Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3046% above fair value
$29.45+0.09 (+0.31%)
Close on Nov 11, 2026Market cap $167.86BP/E 42.1Yield 5.84%
Pfizer EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Pfizer's EPS for the twelve months ending Sep 27, 2026 was $0.70, down 59.3% year over year. For fiscal 2025 it was $1.36, down 3.5% from the year before. Over ten years it grew 2.1% a year on average. The highest annual figure on record is $5.47 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36 | -3.5% |
| FY2024 | Dec 31, 2024 | $1.41 | +281.1% |
| FY2023 | Dec 31, 2023 | $0.37 | -93.2% |
| FY2022 | Dec 31, 2022 | $5.47 | +42.1% |
| FY2021 | Dec 31, 2021 | $3.85 | +136.2% |
| FY2020 | Dec 31, 2020 | $1.63 | -42.2% |
| FY2019 | Dec 31, 2019 | $2.82 | +50.8% |
| FY2018 | Dec 31, 2018 | $1.87 | -46.9% |
| FY2017 | Dec 31, 2017 | $3.52 | +200.9% |
| FY2016 | Dec 31, 2016 | $1.17 | +5.4% |
| FY2015 | Dec 31, 2015 | $1.11 | -21.8% |
| FY2014 | Dec 31, 2014 | $1.42 | -55.5% |
| FY2013 | Dec 31, 2013 | $3.19 | +64.4% |
| FY2012 | Dec 31, 2012 | $1.94 | +52.8% |
| FY2011 | Dec 31, 2011 | $1.27 | +24.5% |
| FY2010 | Dec 31, 2010 | $1.02 | -17.1% |
| FY2009 | Dec 31, 2009 | $1.23 | +2.5% |
| FY2008 | Dec 31, 2008 | $1.20 | +2.6% |
| FY2007 | Dec 31, 2007 | $1.17 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $0.56 | -9.7% |
| Q2 FY2026 | Jun 28, 2026 | -$0.04 | -107.8% |
| Q1 FY2026 | Mar 29, 2026 | $0.47 | -9.6% |
| Q4 FY2025 | Dec 31, 2025 | -$0.29 | -514.3% |
| Q3 FY2025 | Sep 28, 2025 | $0.62 | -20.5% |
| Q2 FY2025 | Jun 29, 2025 | $0.51 | +5000.0% |
| Q1 FY2025 | Mar 30, 2025 | $0.52 | -5.5% |
| Q4 FY2024 | Dec 31, 2024 | $0.07 | – |
| Q3 FY2024 | Sep 29, 2024 | $0.78 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.01 | -97.6% |
| Q1 FY2024 | Mar 31, 2024 | $0.55 | -43.3% |
| Q4 FY2023 | Dec 31, 2023 | -$0.59 | -167.8% |
| Q3 FY2023 | Oct 1, 2023 | -$0.42 | -127.8% |
| Q2 FY2023 | Jul 2, 2023 | $0.41 | -76.3% |
| Q1 FY2023 | Apr 2, 2023 | $0.97 | -29.2% |
| Q4 FY2022 | Dec 31, 2022 | $0.87 | +47.5% |
| Q3 FY2022 | Oct 2, 2022 | $1.51 | +6.3% |
| Q2 FY2022 | Jul 3, 2022 | $1.73 | +76.5% |
| Q1 FY2022 | Apr 3, 2022 | $1.37 | +59.3% |
| Q4 FY2021 | Dec 31, 2021 | $0.59 | +293.3% |
| Q3 FY2021 | Oct 3, 2021 | $1.42 | +446.2% |
| Q2 FY2021 | Jul 4, 2021 | $0.98 | +58.1% |
| Q1 FY2021 | Apr 4, 2021 | $0.86 | +43.3% |
| Q4 FY2020 | Dec 31, 2020 | $0.15 | – |
| Q3 FY2020 | Sep 27, 2020 | $0.26 | -80.9% |
| Q2 FY2020 | Jun 28, 2020 | $0.62 | -30.3% |
| Q1 FY2020 | Mar 29, 2020 | $0.60 | -11.8% |
| Q4 FY2019 | Dec 31, 2019 | -$0.10 | – |
| Q3 FY2019 | Sep 29, 2019 | $1.36 | +97.1% |
| Q2 FY2019 | Jun 30, 2019 | $0.89 | +36.9% |
| Q1 FY2019 | Mar 31, 2019 | $0.68 | +15.3% |
| Q4 FY2018 | Dec 31, 2018 | -$0.07 | -103.4% |
| Q3 FY2018 | Sep 30, 2018 | $0.69 | +46.8% |
| Q2 FY2018 | Jul 1, 2018 | $0.65 | +27.5% |
| Q1 FY2018 | Apr 1, 2018 | $0.59 | +15.7% |
| Q4 FY2017 | Dec 31, 2017 | $2.03 | +1461.5% |
| Q3 FY2017 | Oct 1, 2017 | $0.47 | – |
| Q2 FY2017 | Jul 2, 2017 | $0.51 | – |
| Q1 FY2017 | Apr 2, 2017 | $0.51 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.13 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?